LGNZZ supply chain intelligence for LIGAND PHARMACEUTICALS INC: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
LIGAND PHARMACEUTICALS INC (LGNZZ) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ANEB graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrote… |
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| CURX | Curanex Pharmaceuticals Inc | 72% | Reciprocal relationship from CURX graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrote… |
| CURX | Curanex Pharmaceuticals Inc | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH… |
| HTGC | Hercules Capital, Inc. | 72% | rketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following approval. Zydus Ca… |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from LGNZZ graph: rketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Accrued financial royalty asset purchases $ $ Accrued fixed asset purchases $ $ Unrealized gain (loss) on AFS investments, net of tax $ ( ) $ See accompanying notes to unaudited condensed consolidate… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LGNZZ graph: Accrued financial royalty asset p… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from LGNZZ graph: h epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the init… |
| LLY | Eli Lilly and Company | 72% | h epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is i… |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | Reciprocal relationship from OBIO graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from OBIO graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from OBIO… |
| PTHS | Pelthos Therapeutics Inc. | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| PTHS | Pelthos Therapeutics Inc. | 72% | Reciprocal relationship from PTHS graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrote… |
| SNYNF | Sanofi | 72% | h epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is i… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGNZZ graph: h epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the in… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| ANEB | Anebulo Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ANEB graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from ANEB graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As… |
| CURX | Curanex Pharmaceuticals Inc | 72% | Reciprocal relationship from CURX graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from CURX graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As… |
| CURX | Curanex Pharmaceuticals Inc | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net … |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from LGNZZ graph: rketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to… |
| HTGC | Hercules Capital, Inc. | 72% | rketed in India for breast cancer. Zydus Cadila uses the Selexis technology platform for Vivitra. We are entitled to earn royalties on sales by Zydus Cadila for ten years following approval. Zydus Ca… |
| JJETF | JJETF | 72% | Reciprocal relationship from JJETF graph: Reciprocal relationship from LGNZZ graph: is being amortized to interest expense using the effective interest method over the expected life of the 2023 Notes… |
| JJETF | JJETF | 72% | is being amortized to interest expense using the effective interest method over the expected life of the 2023 Notes. The effective interest rate for the year ended December 31, 2023 is %. During the … |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Accrued financial royalty asset purchases $ $ Accrued fixed asset purchases $ $ Unrealized gain (loss) on AFS investments, net of tax $ ( ) $ See accompanying notes to unaudited condensed consolidate… |
| LGND | Ligand Pharmaceuticals Incorporated | 72% | Reciprocal relationship from LGND graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LGNZZ graph: Accrued financial royalty asset p… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from LLY graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from LLY gr… |
| LLY | Eli Lilly and Company | 72% | h epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is i… |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | Reciprocal relationship from OBIO graph: Reciprocal relationship from LGNZZ graph: expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrote… |
| OBIO | Orchestra BioMed Holdings, Inc. | 72% | expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a … |
| OVID | Ovid Therapeutics Inc. | 72% | Reciprocal relationship from OVID graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from OVID graph: Reciprocal relationship from LGNZZ graph: R Holders $ ( ) $ ( ) Supplementa… |
| OVID | Ovid Therapeutics Inc. | 72% | R Holders $ ( ) $ ( ) Supplemental cash flow disclosures: Purchases of property, plant and equipment included in accounts payable and accrued expenses $ $ 5. $ ( ) $ $ $ ( ) $ Selexis and Dianomi ( )… |
| PTHS | Pelthos Therapeutics Inc. | 72% | Reciprocal relationship from PTHS graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from PTHS graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from PTHS… |
| PTHS | Pelthos Therapeutics Inc. | 72% | ervable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our… |
| PVLA | Palvella Therapeutics, Inc. | 72% | Reciprocal relationship from PVLA graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from PVLA graph: Reciprocal relationship from LGNZZ graph: R Holders $ ( ) $ ( ) Supplementa… |
| PVLA | Palvella Therapeutics, Inc. | 72% | R Holders $ ( ) $ ( ) Supplemental cash flow disclosures: Purchases of property, plant and equipment included in accounts payable and accrued expenses $ $ 5. $ ( ) $ $ $ ( ) $ Selexis and Dianomi ( )… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from SN… |
| SNYNF | Sanofi | 72% | d December 31, 2023 and 2022 were allocated accordingly between revenue and the amortization of the commercial license rights. We had accounted for commercial license rights related to Dianomi on a n… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: from non-elective hip fracture surgery. However, VK5211, if approved, will face competition from experimental therapies that are in various stages of clinical… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| LGNZZ-DEBT-10695 | Warrants outstanding: 3264643 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| LGNZZ-DEBT-10696 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PVLA | Palvella Therapeutics, Inc. | 100.00 | 1 | ['customer'] |
| PTHS | Pelthos Therapeutics Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| OBIO | Orchestra BioMed Holdings, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DNTH | Dianthus Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CURX | Curanex Pharmaceuticals Inc | 100.00 | 1 | ['customer', 'supplier'] |
| ANEB | Anebulo Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JJETF | BARCLAYS BANK PLC | 100.00 | 1 | ['customer'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| OVID | Ovid Therapeutics Inc. | 100.00 | 1 | ['customer'] |
| VKTX | Viking Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| HMDCF | HUTCHMED (China) Ltd | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 50.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 50.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 | |
| CYCN | Cyclerion Therapeutics, Inc. | 50.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 50.00 | 2 | |
| BHC | Bausch Health Companies Inc. | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 |